A Valeant offer for Afexa Life Sciences

Afexa Life Sciences, the maker of Cold-FX, finds its white knight.

Aug 30, 2011

by Max Fawcett

by Max Fawcett, Managing Editor

Last week, Edmonton’s Afexa Life Sciences announced that it was looking for a so-called white knight to save it from a hostile takeover bid from Paladin Labs. Today, they got it. Valeant Pharmaceuticals International – the company formerly known as Biovail – made a friendly bid on Tuesday, offering $76 million for the maker of Cold-FX. That bid is substantially higher than Paladin’s $56.7 million offer.

Valeant chairman and CEO Michael Pearson announced that his company’s bid has the full support of Afexa’s management team and board of directors. He described the deal as “a transaction that we believe should deliver significant benefits to our customers, employees and shareholders.”

Afexa and Valeant have agreed to a 30-day “go shop” period during which Afexa can continue to solicit new bids. Under the terms of the agreement, Valeant has the right to match any new bid.

August 2011 Contents

Trackback URI | Comments RSS

You may also like these stories

Cold-FX Heats Up

The maker of Cold-FX is fighting a hostile takeover bid from Paladin Labs. Is there anyone willing to save it?
Encana sells 40 per cent of Cutbank Ridge to Mitsubishi

Later today, Calgary-based Encana will officially announce that it will sell a 40 per cent stake in its Cutbank Ridge assets in Northeastern B.C. to Mitsubishi Corp. for $2.9 billion (half in cash, half in development costs over the next five years).
Alberta the fastest-growing province, says Statscan

Calgary and Edmonton the two fastest-growing cities
Editor's Note: Heroes And Villains

Polarization as the dominant pattern in our public debates
BizBeat relaunch

Enbridge makes a pitch for Northern Gateway